# OpenAI buys Orchestra Bio to expand biotech AI

> OpenAI acquires AI drug-discovery startup Orchestra Bio and folds its team into Rosalind, its life sciences research model.
- Title: OpenAI buys Orchestra Bio to expand biotech AI · TechCrunch
- Summary: OpenAI acquires AI drug-discovery startup Orchestra Bio and folds its team into Rosalind, its life sciences research model. OpenAI acquired biotech startup…
- Keywords: openai, orchestra bio, biotech, ai acquisition, rosalind, drug discovery, moderna, novo nordisk, technology, startups, buys, Orchestra
- Source: TechCrunch — https://techcrunch.com/2026/10/20/openai-acquires-startup-orchestra-bio%e2%81%a0-to-beef-up-its-biotech-business
- Author: Julie Bort
- Published: 2026-10-20T20:35:10+00:00
- Read time: 1 min
- Topics: openai, orchestra bio, biotech, ai acquisition, rosalind, drug discovery, moderna, novo nordisk, technology, startups
## OpenAI acquires Orchestra Bio
OpenAI acquired four-year-old AI biotech software startup Orchestra Bio on Tuesday. The company had raised around twenty million dollars as of twenty twenty-five from backers including Andreessen Horowitz, Atria, and eight VC.
## What Orchestra Bio does
Orchestra creates AI agents that help biotech companies manage drug-discovery operations, from tracking finances to resolving scheduling issues with clinical trials.
## Integration with Rosalind
OpenAI is adding Orchestra's team and technology to Rosalind, its AI model for life sciences research, and to Rosalind Workbench, a tool that helps researchers plan experiments and analyze results.
## AI labs absorbing startups
The acquisition shows how the biggest AI labs, namely OpenAI and Anthropic, are building software for major industries like pharma.
## Key takeaway

OpenAI acquired biotech startup Orchestra Bio on Tuesday to strengthen its Rosalind AI model for life sciences research, which already counts Moderna and Novo Nordisk as customers.